Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

 

The Mitotane Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period.

Over the years, mitotane has become one the preferred choices of treatment for Cushing’s syndrome and ACC. The growth of the mitotane market can be attributed to the increased incidence of patient population, which is anticipated to grow significantly in the forecast period. Furthermore, late recurrence of Cushing’s syndrome and late diagnosis and detection also favours the growth of the mitotane market.  ACC has been marked with a high recurrence rate, where treatment using adjuvant therapy has been found to be extremely successful.

How About Looking Through The Sample Of Mitotane Market Report? https://www.persistencemarketresearch.com/samples/30052

The ~US$ 12 billion market for mitotane is anticipated to grow at a healthy CAGR over the period of next decade. Macro-economic factors, such increase expenditure in healthcare sector in emerging nations such as China, India, and Brazil is expected to boost the growth of the mitotane market in the forecast period. With the rise and continual growth in global healthcare expenditure, sales of pharma drugs such as mitotane in countries outside the U.S. represent a potential growth avenue for domestic manufacturers.

Company Profiles:

  • HRA Pharma
  • Bristol-Myers Squibb Company

How About Step-By-Step Insights To Mitotane Market? Look Through The “Methodology” Employed! https://www.persistencemarketresearch.com/methodology/30052

According to the World Bank, all regions (except Sub-Saharan Africa) have seen an increase in the healthcare spending as a percentage of total output over the last two decades. Similarly, in 2016, China’s healthcare expenditure grew ~5% of the GDP, which is expected to almost double by 2020.

The market for mitotane is based on two disease indications such as Cushing’s syndrome and ACC. Cushing’s syndrome includes symptoms such as round red face, high blood pressure, weak muscles and bones, abdominal obesity, a fat lump between shoulders, and fragile skin. The prevalence rate varies from 10-15 cases/ million population/year. High disease diagnosis screening percentage and attractive reimbursement in developed markets have made the mitotane market to grow significantly.

In contrast, ACC is a rare but aggressive tumour that arises from adrenal cortex and develops late with a large mass. It is estimated that ~600 new cases are diagnosed every year/million population. The disease is most common between 50 and 60 years of age. According to PMR, ACC-based disease indication is anticipated to hold a prominent position in the global mitotane market, in terms of revenue with a global market share of ~60% in 2029.

Major players in the mitotane market are focusing on investing in research and development for the improvement of mitotane with less side effects, and introduction of more affordable and reliable drug treatments in developing regions of the world. Besides, companies are also engaged in commercial partnerships for the sales and marketing of mitotane. Such developments are likely to foster the market to grow in untapped regions and meet the treatment demand.

The mitotane market report offers a comprehensive taxonomy based on the disease indication, distribution channel, and region. Based on disease indication, the global mitotane market is segmented into ACC and Cushing’s syndrome.

Based on distribution channel, the mitotane market is classified into hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. With the increase in the incidence of both the diseases and growth opportunities in terms of sales, the mitotane market also offers significant potential for other players to invest in the market.

The mitotane market has been studied across North America, Latin America, Europe, East Asia, South Asia, Oceania, MEA, and Emerging countries such as China, Brazil, and India. Availability of knowledge-based resources and enhanced research collaboration trends in North America and Europe are estimated to propel the growth of the mitotane market. North America and Europe markets are projected to be the prominent regional markets for mitotane and are poised to offer substantial opportunities.

Want To Keep A Tab On The Latest Findings In The Mitotane Market? Purchase Our Mitotane Market Report Now! https://www.persistencemarketresearch.com/checkout/30052

Besides, these regions continue to witness high recurrence rate of adrenocortical carcinoma. Use of adjuvant therapy using mitotane has been the prime success factor in the treatment of such indication. With several collaborations, acquisitions, and agreements between drug industry players and academic institutions are anticipated to help the mitotane market to continually expand and create new dimensions and opportunities for the development of therapeutics for diseases such as ACC and Cushing’s syndrome.

Some of the key companies working in the global mitotane market are HRA Pharma and Bristol-Myers Squibb Company. Continuous investments by big players in product development have led to the commercialization of mitotane drugs with the ability to incorporate in adjuvant-based medications, which can be used in the treatment of both ACC and Cushing’s syndrome.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

 

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts